BOSTON — Pre-exposure prophylaxis, or PrEP, may reduce lifetime HIV risk and increase population life expectancy and lifetime costs of care in South African women, according to results from a simulation model of HIV screening and disease.
“While short-term trials have reported the efficacy
of PrEP, there are several questions that the trials could not answer,”
Rochelle Walensky, MD, MPH, associate professor of medicine at Harvard
Medical School said during a press conference. “We used two efficacy
estimates from the CAPRISA 004 and global iPrEx studies to project the
cost-effectiveness of PrEP in heterosexual women in South Africa.” More »